Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/03/18/2848135/0/en/Inventiva-announces-positive-results-from-the-Phase-II-LEGEND-Proof-of-Concept-study-combining-lanifibranor-with-empagliflozin-in-patients-with-MASH-NASH-and-T2D.html
https://endpts.com/inventiva-stock-sinks-20-after-serious-adverse-event-in-nash-trial-leads-to-enrollment-pause/
https://www.globenewswire.com//news-release/2024/02/15/2830422/0/en/Inventiva-reports-preliminary-2023-fiscal-year-financial-Information-and-provides-an-update-on-its-clinical-trial-NATiV3.html
https://www.globenewswire.com//news-release/2024/01/24/2816082/0/en/Half-Year-Review-of-Inventiva-s-Liquidity-Contract-with-Kepler-Cheuvreux.html
https://www.globenewswire.com//news-release/2024/01/10/2807470/0/en/Inventiva-draws-down-the-second-tranche-of-25-million-under-existing-Finance-Contract-with-the-European-Investment-Bank.html
https://www.globenewswire.com//news-release/2023/12/20/2799634/0/en/Inventiva-announces-the-randomization-of-the-first-patient-in-China-in-the-NATiV3-clinical-trial-and-provides-an-update-on-its-clinical-development-program.html
https://www.globenewswire.com//news-release/2023/12/04/2790438/0/en/Inventiva-announces-the-positive-recommendation-of-the-third-DMC-of-the-Phase-III-clinical-trial-with-lanifibranor-in-patients-with-NASH.html
https://www.globenewswire.com//news-release/2023/11/21/2784410/0/en/Inventiva-reports-2023-Third-Quarter-Financial-Information.html
https://www.globenewswire.com//news-release/2023/11/06/2774457/0/en/Inventiva-announces-a-late-breaker-abstract-and-two-additional-abstracts-on-its-lead-compound-lanifibranor-at-the-AASLD-The-Liver-Meeting-2023.html
https://www.globenewswire.com//news-release/2023/09/28/2751617/0/en/Inventiva-reports-its-2023-first-half-financial-results-and-provides-a-corporate-update.html